A Phase II Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Keynote 497; LUX-Lung IO
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 26 Nov 2018 Planned End Date changed from 25 Feb 2021 to 9 Oct 2020.
- 31 Aug 2018 Biomarkers information updated
- 21 Aug 2018 Planned primary completion date changed from 28 Jun 2019 to 29 Jul 2019.